Incyte Corporation (INCY) Stock Performance and Q1 Earnings Analysis
Incyte Corporation's stock has outperformed both the S&P 500 Index and iShares Biotechnology ETF over the past year, despite a slight YTD decline. The company reported strong first-quarter results with revenue rising to $1.3 billion and adjusted EPS of $1.81, surpassing analyst expectations.